# Clinical Significance and Potential Molecular Mechanisms of Angiotensin-Converting Enzyme 2 in Colorectal Cancer

**Authors:** Da Tong Zeng, Li Yang, Jia Ying Wen, Ke Jun Wu, Guo Qiang Chen, Zong Yu Li, Jing Wen Ling, Bei Bei Huang, Ying Yi Xie, Yi Yu Dong, Ye Ying Fang, Dan Ming Wei, Gang Chen, Lin Shi, Wei Jian Huang

PMC · DOI: 10.14740/wjon2650 · World Journal of Oncology · 2025-12-17

## TL;DR

This study explores how ACE2, a protein linked to tumor suppression, behaves in colorectal cancer and its connection to immune responses and cancer mutations.

## Contribution

The study reveals new insights into ACE2's role in colorectal cancer, linking its expression to nerve invasion, tumor type, and immune suppression.

## Key findings

- ACE2 is upregulated in colorectal cancer cells and Ki-67-activated regions.
- High ACE2 levels correlate with nerve invasion, mucinous adenocarcinoma, and NRAS mutations.
- ACE2 expression is inversely related to CD8+ T-cell infiltration and PD-L1 levels.

## Abstract

Angiotensin-converting enzyme 2 (ACE2) exhibits tumor-suppressive potential in cancers, but its role in colorectal cancer (CRC) is unclear. The aim of the study was to investigate ACE2 expression, clinical significance, and immune microenvironment associations in CRC.

A multidimensional approach was taken using single-cell RNA sequencing and spatial transcriptomics to analyze ACE2 expression in CRC cells. High-throughput data from the Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) (2,275 CRC and 1,269 adjacent tissues) were used to assess mRNA levels. Immunohistochemistry was performed to examine ACE2 protein expression in 66 CRC and 75 adjacent tissues. Molecular testing assessed associations with Kirsten rat sarcoma viral oncogene homolog (KRAS), neuroblastoma RAS viral oncogene homolog (NRAS), and B-Raf proto-oncogene, serine/threonine kinase (BRAF) mutations. Immune infiltration was analyzed using single-sample gene set enrichment analysis (ssGSEA), focusing on 24 immune cell types, CD8+ T cells, and programmed death ligand 1 (PD-L1) correlations.

ACE2 was highly expressed in malignant cells and Ki-67-activated regions. mRNA and protein levels were upregulated in CRC (standardized mean difference (SMD) = 0.321, area under the curve (AUC) = 0.844). High ACE2 exhibited significant associations with nerve invasion, lower expression in mucinous adenocarcinomas, and NRAS (Q61R/L/H/K) mutations. ACE2 negatively showed an inverse correlation with CD8+ T-cell infiltration (r = -0.186, P < 0.001) and PD-L1 expression (r = -0.282, P = 0.022).

The upregulation of ACE2 is associated with nerve invasion, pathological type, and an immunosuppressive microenvironment with reduced CD8+ T-cell infiltration and PD-L1 expression.

## Linked entities

- **Genes:** ACE2 (angiotensin converting enzyme 2) [NCBI Gene 59272], KRAS (KRAS proto-oncogene, GTPase) [NCBI Gene 3845], NRAS (NRAS proto-oncogene, GTPase) [NCBI Gene 4893], BRAF (B-Raf proto-oncogene, serine/threonine kinase) [NCBI Gene 673], CD8A (CD8 subunit alpha) [NCBI Gene 925], CD274 (CD274 molecule) [NCBI Gene 29126], Mki67 (antigen identified by monoclonal antibody Ki 67) [NCBI Gene 17345]
- **Proteins:** ACE2 (angiotensin converting enzyme 2), CD274 (CD274 molecule)
- **Diseases:** colorectal cancer (MONDO:0005575), mucinous adenocarcinoma (MONDO:0004957)

## Full-text entities

- **Genes:** Ace2 (angiotensin converting enzyme 2) [NCBI Gene 302668], Taok2 (TAO kinase 2) [NCBI Gene 64666] {aka Tao2}, Braf (B-Raf proto-oncogene, serine/threonine kinase) [NCBI Gene 114486]
- **Diseases:** Cancer (MESH:D009369), mucinous adenocarcinomas (MESH:D002288), CRC (MESH:D015179), nerve invasion (MESH:D009361)
- **Mutations:** Q61R/L, serine/threonine

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12758057/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12758057/full.md

## References

82 references — full list in the complete paper: https://tomesphere.com/paper/PMC12758057/full.md

---
Source: https://tomesphere.com/paper/PMC12758057